Recent Research Funding

Jad Z. Bou-Abdallah, MD.

“Our division's funding bolsters and propels clinical research,” says Jad Z. Bou-Abdallah, MD, who studies the impact of clopidogrel, an antiplatelet drug, on colonoscopies.

Our faculty and fellows conduct novel research backed by generous extramural and intramural funding.

Supported by grants from an assortment of sources, our physician-scientists are uniquely poised to embark on clinical, translational and basic research in a variety of areas.

We've received competitively awarded funding from sources including:

  • National Institutes of Health
  • Centers for Disease Control and Prevention 
  • U.S. Department of Veterans Affairs

Our division’s research has also received support from biotechnology and pharmaceutical companies. 

Our funded research efforts include:

Andrew Talal, MD, MPH

  • Patient-Centered HCV Care via Telemedicine for Individuals on Opiate Substitution Therapy: A Stepped Wedge Cluster Randomized Controlled Trial. Andrew Talal (Principal Investigator). Patient-Centered Outcomes Research Institute (PCORI). $7,000,000. 11/1/2016-7/1/2024.
  • NIH/NIAID (Morse) HIV/AIDS Clinical Trial Unit. Andrew Talal (Co-Principal Investigator). 12/1/2013-4/1/2028.
  • NIH/NIDDK (Shapiro) Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study. Andrew Talal (Co-Principal Investigator). 8/1/2020-6/1/2024.
  • Troup Fund/Kaleida Health Foundation Liver Center of Western New York. Andrew Talal (Principal Investigator). Troup Fund/Kaleida Health Foundation Liver Center of Western New York. $3,067,590. 7/1/2018-6/1/2025.
  • A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (Eli Lilly and Company). Andrew Talal (Principal Investigator). Eli Lilly and Company. 1/1/2019-12/1/2022.
  • A Phase 2B Randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (Bristol-Myers Squibb). Andrew Talal (Principal Investigator). Bristol-Myers Squibb. 1/1/2019-12/1/2022.
  • A Phase 2B Randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis (Bristol-Myers Squibb). Andrew Talal (Principal Investigator). Bristol-Myers Squibb. 1/1/2019-12/1/2022.
  • A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis. Andrew Talal (Principal Investigator). Intercept Pharmaceuticals. 1/1/2018-12/1/2023.
  • A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis. Andrew Talal (Principal Investigator). Intercept Pharmaceutical. 1/1/2015-12/1/2023.